Skip to content
Screener

Jade Biosciences JBIO Q4 2025 Annual earnings

Reported March 6, 2026 · Before market open

EPS-$0.11Beat by $0.34
EPS estimate-$0.45

Next report

Aug 12, 2026 (In 2 days)
EPS estimate-$0.66

Financials

Q4 2025

Income statement

See full
Operating income-$35.0M+1.6%
Net income-$31.9M+32.0%
EPS (diluted)-$0.11+99.3%

Balance sheet

See full
Cash & equivalents$88.4M+27.5%
Total debt$851.0K+104%
Total equity$332.5M+811%
Total assets$349.8M+380%

Cash flow

See full
Operating cash flow-$33.6M-48.8%
CapEx$3.0K—
Free cash flow-$33.7M—

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$760.92M—
Enterprise value$673.33M—

Returns & leverage

See full
Debt / equity0×—
Current ratio21.1×+15.3×

FAQ

When did Jade Biosciences report Q4 2025 earnings?
Jade Biosciences (JBIO) reported Q4 2025 earnings on March 6, 2026 before market open.
What were Jade Biosciences's Q4 2025 revenue and EPS?
Jade Biosciences reported eps of $-0.11 for Q4 2025.
Did Jade Biosciences beat estimates in Q4 2025?
EPS beat the consensus estimate of $-0.45 by $0.34.
How did Jade Biosciences's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 42.1% from $-0.19.
Where can I find Jade Biosciences's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-094967) and the 10-K periodic report (0001193125-26-096550) directly on SEC EDGAR. The filing index links above go to sec.gov.